Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“005) compared with patients treated with capecitabine/trastuzumab/placebo.(62) This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade 3, but did not lead to frequent treatment discontinuation.”
Self-citationMosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Self-citationTreatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 832
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationSaura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Self-citationBreast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
“The HER2CLIMB randomized, double-blind, placebocontrolled trial compared tucatinib versus placebo in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and T-DM1.(21) The trial was unique in that it enrolled a large pro…”
BackgroundMethodInfluentialSelf-citationSperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., Nesbit, E., Kruser, T. J., Chan, J., Braunstein, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01255 · Cited by 471
“100 184 (7) 23 (12-42) 94 (6) 25 (12-49) 57 (9) 14 (7-33) 62 (9) 28 (10-102) 110 (13) 17 (8-42) 55 (7) 16 (7-26)”
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023: Featured Updates to the NCCN Guidelines
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0031 · Cited by 453
Self-citationChallenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
“In addition, significant results were obtained when tucatinib was used in combination with trastuzumab and capecitabine for patients with HER2-positive metastatic breast cancer [118].”
BackgroundXu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q., Tong, Z., Li, H., Zhang, Q., Sun, T., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30702-6 · Cited by 402
André, F., Hee Park, Y., Kim, S.-B., Takano, T., Im, S.-A., Borges, G., Lima, J. P., Aksoy, S., Gavila Gregori, J., De Laurentiis, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00725-0 · Cited by 379
Self-citationBartsch, R., Berghoff, A. S., Furtner, J., Marhold, M., Bergen, E. S., Roider-Schur, S., Starzer, A. M., Forstner, H., Rottenmanner, B., Dieckmann, K., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01935-8 · Cited by 389
Montemurro, F., Delaloge, S., Barrios, C. H., Wuerstlein, R., Anton, A., Brain, E., Hatschek, T., Kelly, C. M., Peña-Murillo, C., Yilmaz, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.020 · Cited by 349
“Our reported median PFS, based on a large number of patients and events, is within the range of those described with lapatinib or neratinib plus capecitabine in patients with BM,(7,13) while the three-drug combination of tucatinib, trastuzumab, and capecitabine yielded superior median PFS in the HER2CLIMB trial.(17) I…”
ResultSignaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
“Tucatinib has been recently approved by the FDA in combination with trastuzumab and capecitabine, an anti-metabolite, for the treatment of metastatic HER2+ breast cancer [72].”
BackgroundProperties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Schlam, I., & Swain, S. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00265-1 · Cited by 290
The blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 287
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S., Tu, H.-Y., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 288
“As the development of brain metastases is common in HER2-mutant lung cancers, affecting 47% of patients, central nervous system activity should be further evaluated in future trials as it is in breast cancer trials (42, 43).”
BackgroundSelf-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Invasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition
Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R. J., Luengo, A., Davidson, S. M., Ali, A., Ferraro, G. B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1228 · Cited by 272
Cardoso, F., Paluch-Shimon, S., Schumacher-Wulf, E., Matos, L., Gelmon, K., Aapro, M. S., Bajpai, J., Barrios, C. H., Bergh, J., Bergsten-Nordström, E., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103756 · Cited by 237
Self-citationTolaney, S. M., Wardley, A. M., Zambelli, S., Hilton, J. F., Troso-Sandoval, T. A., Ricci, F., Im, S.-A., Kim, S.-B., Johnston, S. R., Chan, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30112-1 · Cited by 258
Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance
Mo, F., Pellerino, A., Soffietti, R., & Rudà, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312654 · Cited by 245
Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03261-7 · Cited by 227
Self-citationPérez-García, J. M., Vaz Batista, M., Cortez, P., Ruiz-Borrego, M., Cejalvo, J. M., de la Haba-Rodriguez, J., Garrigós, L., Racca, F., Servitja, S., Blanch, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac144 · Cited by 246
“4 Until the HER2CLIMB trial, there was limited clinical evidence for systemic management of patients with active BCBMs. 10 HER2CLIMB was the first randomized study to demonstrate an improved antitumor activity in terms of progression-free survival (PFS) and overall survival (OS) of a…”
BackgroundMethodInfluentialSelf-citationBreast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 214
Ferraro, E., Drago, J. Z., & Modi, S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01459-y · Cited by 220
“Recently, the newly approved HER2-targeted tyrosine kinase inhibitors tucatinib and neratinib have shown significant clinical benefit in the treatment of stable as well as progressive or untreated BMs, although no direct comparison with the new ADCs is yet available [41, 42].”
BackgroundZou, Y., Zheng, S., Xie, X., Ye, F., Hu, X., Tian, Z., Yan, S.-M., Yang, L., Kong, Y., Tang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30217-7 · Cited by 226
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
Kunte, S., Abraham, J., & Montero, A. J. (2020) · Cancer · doi:10.1002/cncr.33102 · Cited by 214
“Grade ≥3 adverse events that were more commonly associated with tucatinib included diarrhea (13%) and transaminitis (5%).(29) On the basis of these results, the FDA recently granted approval to the combination for the treatment of patients with unresectable, HER2– positive, locally advanced breast cancer or MBC after…”
BackgroundCurigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.005 · Cited by 217
Self-citationKulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Lin, N. U., Murthy, R. K., Abramson, V., Anders, C., Bachelot, T., Bedard, P. L., Borges, V., Cameron, D., Carey, L. A., Chien, A. J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5610 · Cited by 208
Self-citationEmerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 194
“Tucatinib also showed improved efficacy in reducing brain metastasis [176,177].”
BackgroundSmall molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Antibody–drug conjugates: in search of partners of choice
Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.01.003 · Cited by 201
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Giordano, S. H., Franzoi, M. A. B., Temin, S., Anders, C. K., Chandarlapaty, S., Crews, J. R., Kirshner, J. J., Krop, I. E., Lin, N. U., Morikawa, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00519 · Cited by 176
“This recommendation is based on a single RCT of tucatinib, trastuzumab, and capecitabine.(15) Six hundred twelve patients were randomly assigned to this triplet versus trastuzumab, capecitabine, and placebo; 480 were included in primary outcome (PFS) analysis (320 v 160).”
MethodSelf-citationCurrent and Future Management of HER2-Positive Metastatic Breast Cancer
Martínez-Sáez, O., & Prat, A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00172 · Cited by 183
“DS-8201a DS-8201a is an ADC composed of trastuzumab, a linker, and a potent topoisomerase I inhibitor as the cytotoxic drug (payload) with a drug-to-antibody ratio of approximately 8.36 In addition, DS-8201a has a cytotoxic effect on neighboring tumor cells regardless of target expression because of a released payload…”
BackgroundInfluentialEvolving standards of care and new challenges in the management of HER2‐positive breast cancer
Choong, G. M., Cullen, G. D., & O’Sullivan, C. C. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21634 · Cited by 176
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Wei, Q., Li, P., Yang, T., Zhu, J., Sun, L., Zhang, Z., Wang, L., Tian, X., Chen, J., Hu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01509-2 · Cited by 167
Carvalho, M. E. S., Canberk, Ş., Schmitt, F. C., & Vale, N. (2025) · Cancers · doi:10.3390/cancers17071102 · Cited by 214
“Additionally, a clinical trial using a tyrosine kinase inhibitor (tucatinib), together with trastuzumab and capecitabine, improved OS and PFS, suggesting overcoming therapy resistance [206].”
Management of brain metastases according to molecular subtypes
Soffietti, R., Ahluwalia, M., Lin, N., & Rudà, R. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0391-x · Cited by 171
Self-citationDempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06280-x · Cited by 165
“Cardiotoxicity was reported in < 1% of study participants in either arm [89].”
BackgroundCosta, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 158
Molecular and cellular mechanisms underlying brain metastasis of breast cancer
Hosonaga, M., Saya, H., & Arima, Y. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09881-y · Cited by 161
“The effects of tucatinib in patients with HER2–positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have been reported on [52].”
BackgroundWahby, S., Fashoyin-Aje, L., Osgood, C. L., Cheng, J., Fiero, M. H., Zhang, L., Tang, S., Hamed, S. S., Song, P., Charlab, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3119 · Cited by 153
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 191
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt, J., Rozeboom, B. J., Dey, N., & De, P. K. (2020) · PubMed · Cited by 261
Yan, M., Ouyang, Q., Sun, T., Niu, L., Yang, J., Li, L., Song, Y., Hao, C., Chen, Z., Orlandi, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00716-6 · Cited by 161
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
Moutafi, M. K., Robbins, C. T., Yaghoobi, V., Fernandez, A. I., Martínez-Morilla, S., Xirou, V., Bai, Y., Song, Y., Gaule, P., Krueger, J. S., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00804-9 · Cited by 156
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Patel, A., Unni, N. G., & Peng, Y. S. (2020) · Cancers · doi:10.3390/cancers12082081 · Cited by 165
“Based on the results of the HER2CLIMB trial [31], another novel HER2-targeted agent, tucatinib, was approved in April 2020 [31].”
BackgroundTrastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
Indini, A., Rijavec, E., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094774 · Cited by 153
“In this setting, the main competitor of T-DXd is tucatinib, a highly selective and potent anti-HER2 kinase inhibitor, which has shown promising activity in patients with metastatic breast cancer when combined with trastuzumab and capecitabine [41], specifically in those with active brain metastases [42].”
BackgroundGooding, A. J., & Schiemann, W. P. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0067 · Cited by 152
“Additional TKIs that have shown some efficacy in treating HER2þ breast cancers include the EGFRspecific inhibitor, gefitinib (45, 46), as well as the HER2-specific inhibitor, tucatinib, that has recently been granted FDA approval to be combined with trastuzumab and capecitabine regimens for the treatment of patients w…”
BackgroundTargeting HER2 heterogeneity in breast cancer
Hamilton, E. P., Shastry, M., Shiller, S. M., & Ren, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102286 · Cited by 142
Self-citationResistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 163
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 157
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies
Wang, Y., Ye, F., Liang, Y., & Yang, Q. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01424-8 · Cited by 150
Mamounas, E. P., Untch, M., Mano, M. S., Huang, C., Geyer, C. E., von Minckwitz, G., Wolmark, N., Pivot, X. B., Küemmel, S., DiGiovanna, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.011 · Cited by 150
Self-citationUnderstanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 143
HER2-positive advanced breast cancer treatment in 2020
Cesca, M. G., Vian, L., Cristóvão‐Ferreira, S., Ponde, N. F., & de Azambuja, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102033 · Cited by 135
Saura, C., Modi, S., Krop, I. E., Park, Y. H., Kim, S.-B., Tamura, K., Iwata, H., Tsurutani, J., Sohn, J., Mathias, E., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.001 · Cited by 141
Self-citationGarcía‐Recio, S., Hinoue, T., Wheeler, G. L., Kelly, B., Garrido-Castro, A. C., Pascual, T., de Cubas, A. A., Xia, Y., Felsheim, B., McClure, M. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00491-x · Cited by 193
Self-citationCurrent Molecular Combination Therapies Used for the Treatment of Breast Cancer
Wang, Y., & Minden, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911046 · Cited by 150
“17 HER2CLIMB (NCT02614794) [40,146] III First-line treatment approved by FDA in 2020 Trastuzumab Capecitabine Tucatinib (tyrosine kinase inhibitor) Advanced or HER2+ ABC or MBC Better PFS, OS, and safe”
BackgroundOntogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
Chang, C. A., Jen, J., Jiang, S., Sayad, A., Mer, A. S., Brown, K. R., Nixon, A. M. L., Dhabaria, A., Tang, K. H., Venet, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1265 · Cited by 119
“Newer HER2-TKIs, such as neratinib and tucatinib, have more favorable pharmacologic properties and the latter, in particular, is likely to replace lapatinib in metastatic breast cancer regimens (2,8,9).”
BackgroundCiruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 119
“Disease progression (22) 1 patient did not start palbociclib n = 18 Screening failures Reasons: Missing inclusion/exclusion (4) Inclusion criteria (10) Exclusion criteria (3) Unknown (1)”
BackgroundSelf-citationSubtype switching in breast cancer brain metastases: a multicenter analysis
Hulsbergen, A. F. C., Claes, A., Kavouridis, V. K., Ansaripour, A., Nogarede, C. O., Hughes, M. E., Smith, T. R., Brastianos, P. K., Verhoeff, J. J. C., Lin, N., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa013 · Cited by 120
Self-citationNakamura, Y., Mizuno, N., Sunakawa, Y., Canon, J.-L. R., Galsky, M. D., Hamilton, E. P., Hayashi, H., Jérusalem, G., Kim, S. T., Lee, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00606 · Cited by 123
Self-citationBrain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
García‐Álvarez, A., Papakonstantinou, A., & Oliveira, M. (2021) · Cancers · doi:10.3390/cancers13122927 · Cited by 118
“The pivotal HER2CLIMB phase III trial enrolled patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab and T-DM1, and randomized to receive trastuzumab, capecitabine and tucatinib or placebo [68].”
BackgroundSelf-citationThe genomic landscape of breast cancer brain metastases: a systematic review
Morgan, A. J., Giannoudis, A., & Palmieri, C. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30556-8 · Cited by 116
Jérusalem, G., Park, Y. H., Yamashita, T., Hurvitz, S. A., Modi, S., André, F., Krop, I. E., González, X., You, B., Saura, C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0837 · Cited by 111
Self-citationHER2‐positive breast cancer brain metastasis: A new and exciting landscape
Zimmer, A. S., Swearingen, A. E. D. V., & Anders, C. K. (2020) · Cancer Reports · doi:10.1002/cnr2.1274 · Cited by 141
“Building on that, the HER2CLIMB phase III trial was developed and results were recently reported.(101) The trial randomized 612 patients with ZIMMER ET AL.”
MethodSelf-citationRamakrishna, N. R., Anders, C. K., Lin, N., Morikawa, A., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Franzoi, M. A., Kirshner, J. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00520 · Cited by 116
“1% Previous lines for metastatic cancer, median: 3 (1-14) v 3 (1-13)”
BackgroundSelf-citationLobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
Christgen, M., Cserni, G., Floris, G., Marchiò, C., Djerroudi, L., Kreipe, H. H., Derksen, P. W. B., & Vincent‐Salomon, A. (2021) · Cancers · doi:10.3390/cancers13153695 · Cited by 117
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies
Chaudhari, R. H., Patel, V., & Kumar, A. (2024) · Nanoscale Advances · doi:10.1039/d4na00086b · Cited by 125
Barcenas, C., Hurvitz, S. A., Palma, J. A. D., Bose, R., Chien, A. J., Iannotti, N. O., Marx, G. M., Brufsky, A., Litvak, A. M., Ibrahim, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.012 · Cited by 104
Self-citationTrastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Yu, J., Mu, Q., Fung, M., Xu, X., Zhu, L., & Ho, R. J. Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108108 · Cited by 114
van Mackelenbergh, M., Loibl, S., Untch, M., Buyse, M. E., Geyer, C. E., Gianni, L., Schneeweiß, A., Conte, P., Piccart, M. J., Bonnefoi, H. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02241 · Cited by 113
“Age, years, median (min-max) 49 (18-81) 48 (21-81) 51 (18-81)”
Self-citationTargeting brain metastases in breast cancer
Corti, C., Antonarelli, G., Criscitiello, C., Lin, N., Carey, L., Cortés, J., Poortmans, P. M., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102324 · Cited by 105
Self-citationPI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds
Yuan, Y., Long, H., Zhou, Z., Fu, Y., & Jiang, B. (2023) · Biomolecules · doi:10.3390/biom13010093 · Cited by 108
Breast Cancer Brain Metastasis: A Comprehensive Review
Raghavendra, A. S., & Ibrahim, N. K. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00794 · Cited by 110
Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M. V., & Guarneri, V. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100409 · Cited by 109
“The most prevalent grade 3/4 AEs with tucatinib were palmareplantar erythrodysesthesia, diarrhea, increased liver enzymes, and fatigue.(25) Interestingly, tucatinib was demonstrated to yield an impressive efficacydboth intracranially and extracraniallydin the subgroup of patients with brain metastases, including those…”
BackgroundChemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
Cao, J., Zhang, M., Wang, B., Zhang, L., Zhou, F., & Fang, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658552 · Cited by 114
Ma, F., Yan, M., Li, W., Ouyang, Q., Tong, Z., Teng, Y., Wang, Y., Wang, S., Geng, C., Luo, T., et al. (2023) · BMJ · doi:10.1136/bmj-2023-076065 · Cited by 114
Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortés, J., Curigliano, G., de Azambuja, E., Isacke, C. M., Harbeck, N., Kaidar‐Person, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00534-x · Cited by 99
Self-citation(2021) · doi:10.1038/s43018-021-00190-z · Cited by 92
Self-citationThe emerging roles of NGS in clinical oncology and personalized medicine
Hussen, B. M., Abdullah, S. T., Salihi, A. B., Sabir, D. K., Sidiq, K. R., Rasul, M. F., Hidayat, H. J., Ghafouri‐Fard, S., Taheri, M. N., & Jamali, E. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153760 · Cited by 98
Hurvitz, S. A., Kim, S.-B., Chung, W., Im, S., Park, Y. H., Hegg, R., Kim, M.-H., Tseng, L., Petry, V., Chung, C.-F., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102924 · Cited by 97
Self-citationBreast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Watase, C., Shiino, S., Shimoi, T., Noguchi, E., Kaneda, T., Yamamoto, Y., Yonemori, K., Takayama, S., & Suto, A. (2021) · Cancers · doi:10.3390/cancers13051078 · Cited by 88
“Tucatinib is a highly specific HER2-targeted tyrosine kinase inhibitor with minimal inhibition of the epidermal growth factor receptor [76].”
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 91
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.